The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In the biotech sector, where stock prices are sensitive to clinical trial outcomes, Danish biotech firm Genmab and partner AbbVie announced that their lymphoma drug combination met the primary endpoint in a late-stage (phase 3) trial, as reported by the Wall Street Journal. This success drove Genmab shares higher, reflecting investor optimism about the therapy's potential.
The announcement comes amid intense competition in the oncology space, with drug developers racing to deliver more effective treatments. AbbVie's stock (ABBV) closed at $254.31 on June 29, 2026, per market data. The positive data bolsters AbbVie's oncology pipeline, following its prior strategic acquisitions.
Sign in to access this content
Sign InABBV is currently trading at $254.31 (close June 29), with an intraday range of $249.20 to $255.99. Investors are now watching for the next regulatory steps, as Genmab and AbbVie are expected to file for approval with U.S. and European authorities in the coming months.